OBJECTIVE: This report evaluated the efficacy and tolerability of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder (ADHD), diagnosed using DSM-IV-TR criteria, who did or did not receive prior treatment with stimulants for ADHD by examining pooled data from 3 randomized, double-blind, placebo-controlled studies. METHOD:Three patient populations were evaluated: (1) all patients (i.e., all-patient group), (2) patients who were treated previously with stimulants (i.e., prior-stimulant group), and (3) patients who either were treated previously with ADHD medications other than stimulants or were not treated with any medications for ADHD (i.e., medication- or stimulantnaive group). Tolerability was evaluated by monitoring adverse events reported by both patients and parents. The 3 studies were conducted between November 2003 and June 2004. RESULTS: Of 638 patients randomized, 633 receivedmodafinil (N = 420) or placebo (N = 213), 303 had receivedprior stimulant treatment (modafinil, 194; placebo, 109), and 330 had no prior stimulant experience (modafinil, 226; placebo, 104). Modafinil improved symptoms of ADHD, as assessed by ADHD-RS-IV School Version total scores (mean change from baseline to final visit compared with placebo) in the all-patient group (-16.4 vs. -8.3) (p < .0001), the prior-stimulant group (-14.2 vs. -9.3) (p < .001), and the medication-or stimulant-naive group (-18.3 vs. -7.3) (p < .0001). Similar improvements were observed on the ADHD-RS-IV Home Version and for overall clinical condition. Insomnia, headache, and decreased appetite were the most commonly reported adverse events. Discontinuation because of adverse events was similar in the modafinil and placebo groups (5% vs. 3%). CONCLUSIONS: This post hoc analysis extends previous findings that modafinil was well tolerated and improved the symptoms and behaviors of ADHD at school and at home as assessed by teachers, parents, and clinicians and improved patients' overall clinical condition. Improvements were shown regardless of history of stimulant use.
RCT Entities:
OBJECTIVE: This report evaluated the efficacy and tolerability of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder (ADHD), diagnosed using DSM-IV-TR criteria, who did or did not receive prior treatment with stimulants for ADHD by examining pooled data from 3 randomized, double-blind, placebo-controlled studies. METHOD: Three patient populations were evaluated: (1) all patients (i.e., all-patient group), (2) patients who were treated previously with stimulants (i.e., prior-stimulant group), and (3) patients who either were treated previously with ADHD medications other than stimulants or were not treated with any medications for ADHD (i.e., medication- or stimulantnaive group). Tolerability was evaluated by monitoring adverse events reported by both patients and parents. The 3 studies were conducted between November 2003 and June 2004. RESULTS: Of 638 patients randomized, 633 received modafinil (N = 420) or placebo (N = 213), 303 had received prior stimulant treatment (modafinil, 194; placebo, 109), and 330 had no prior stimulant experience (modafinil, 226; placebo, 104). Modafinil improved symptoms of ADHD, as assessed by ADHD-RS-IV School Version total scores (mean change from baseline to final visit compared with placebo) in the all-patient group (-16.4 vs. -8.3) (p < .0001), the prior-stimulant group (-14.2 vs. -9.3) (p < .001), and the medication-or stimulant-naive group (-18.3 vs. -7.3) (p < .0001). Similar improvements were observed on the ADHD-RS-IV Home Version and for overall clinical condition. Insomnia, headache, and decreased appetite were the most commonly reported adverse events. Discontinuation because of adverse events was similar in the modafinil and placebo groups (5% vs. 3%). CONCLUSIONS: This post hoc analysis extends previous findings that modafinil was well tolerated and improved the symptoms and behaviors of ADHD at school and at home as assessed by teachers, parents, and clinicians and improved patients' overall clinical condition. Improvements were shown regardless of history of stimulant use.
Authors: J Swanson; S Gupta; D Guinta; D Flynn; D Agler; M Lerner; L Williams; I Shoulson; S Wigal Journal: Clin Pharmacol Ther Date: 1999-09 Impact factor: 6.875
Authors: Joseph Biederman; James M Swanson; Sharon B Wigal; Christopher J Kratochvil; Samuel W Boellner; Craig Q Earl; John Jiang; L Greenhill Journal: Pediatrics Date: 2005-12 Impact factor: 7.124
Authors: David Michelson; Albert J Allen; Joan Busner; Charles Casat; David Dunn; Christopher Kratochvil; Jeffrey Newcorn; F Randy Sallee; R Bart Sangal; Keith Saylor; Scott West; Douglas Kelsey; Joachim Wernicke; Nancy J Trapp; Donald Harder Journal: Am J Psychiatry Date: 2002-11 Impact factor: 18.112
Authors: Ronald T Brown; Robert W Amler; Wendy S Freeman; James M Perrin; Martin T Stein; Heidi M Feldman; Karen Pierce; Mark L Wolraich Journal: Pediatrics Date: 2005-06 Impact factor: 7.124
Authors: P S Jensen; S P Hinshaw; J M Swanson; L L Greenhill; C K Conners; L E Arnold; H B Abikoff; G Elliott; L Hechtman; B Hoza; J S March; J H Newcorn; J B Severe; B Vitiello; K Wells; T Wigal Journal: J Dev Behav Pediatr Date: 2001-02 Impact factor: 2.225
Authors: Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Vital Health Stat 11 Date: 2002-05
Authors: Cynthia L Ogden; Robert J Kuczmarski; Katherine M Flegal; Zuguo Mei; Shumei Guo; Rong Wei; Laurence M Grummer-Strawn; Lester R Curtin; Alex F Roche; Clifford L Johnson Journal: Pediatrics Date: 2002-01 Impact factor: 7.124
Authors: M M Lansbergen; M van Dongen-Boomsma; J K Buitelaar; D Slaats-Willemse Journal: J Neural Transm (Vienna) Date: 2010-12-17 Impact factor: 3.575